Choosing her appropriate LOTRONEX dose.

Follow this path to make sure she’s getting her most appropriate
Starting dose: 0.5 mg BID | 4 weeks | Maintain if… -> | Well controlled at 0.5 mg BID |
Increase if...-> | Inadequate relief, but well tolerated: Increase dose to 1 mg BID. |
A dose-response relationship has not been established for serious complications of constipation.1
IMPORTANT SAFETY INFORMATION
If constipation occurs at 0.5 mg BID, discontinue until resolved.
- Once resolved, resume at 0.5 mg QD
- If constipation occurs at the lower dose, discontinue use
If 1 mg BID does not provide adequate control of IBS symptoms after 4 weeks, discontinue use.
In clinical studies1:
- Occurrences of constipation, a frequent and dose-related side effect of LOTRONEX, were generally mild to moderate, transient in nature, and resolved spontaneously with continued treatment or an interruption of treatment
- Following treatment interruption, 78% of affected patients resumed bowel movements within 2 days and were able to re-initiate LOTRONEX treatment
- Approximately 75% of patients who experienced constipation with 1 mg BID reported only 1 episode
If a patient experiences constipation, discontinue LOTRONEX immediately and wait until it subsides
Once resolved: resume at 0.5 mg QD | -> | If constipation recurs at this lower dose, STOP PERMANENTLY |
Reference: 1. LOTRONEX [package insert]. Roswell, GA: Sebela Pharmaceuticals Inc; 2019.